查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1799158

癌症治疗新型药物传输系统的全球市场

Novel Drug Delivery Systems in Cancer Therapy
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年，美国癌症治疗新型药物传输系统的全球市场规模将达到 645 亿美元

2024年，全球癌症治疗新型药物输送系统市场规模估计为213亿美元，预计到2030年将达到645亿美元，在分析期内（2024-2030年）的复合年增长率为20.3%。奈米颗粒是本报告分析的细分市场之一，预计其复合年增长率为18.0%，到分析期结束时市场规模将达到358亿美元。栓塞颗粒细分市场在分析期间内的复合年增长率估计为23.6%。

美国市场规模估计为 58 亿美元，中国市场预期复合年增长率为 26.9%

预计到2024年，美国癌症治疗新型药物传输系统市场规模将达58亿美元。作为世界第二大经济体的中国，预计2030年市场规模将达到150亿美元，在2024-2030年的分析期间内，复合年增长率将达到26.9%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为16.4%和18.0%。在欧洲，预计德国市场的复合年增长率约为16.9%。

全球癌症治疗中的新型药物传输系统—主要趋势和驱动因素总结

为什么新的药物输送系统可能会颠覆传统的癌症治疗

传统化疗长期以来一直受到全身毒性、生物利用度低和缺乏肿瘤特异性等问题的困扰，这些问题影响了疗效和患者的生活品质。新型药物递送系统 (NDDS) 能够将抗癌药物标靶递送至肿瘤部位，同时最大限度地减少对健康组织的损害，并迅速成为肿瘤学领域的一项变革性技术。透过改善药物动力学和克服抗药性机制，NDDS 正在重新定义临床医生治疗复杂且异质性癌症类型的方法。

最重要的技术创新是奈米载体，例如脂质体、树状聚合物、胶束和聚合物奈米颗粒，它们可以包覆细胞毒性药物，并使其在肿瘤微环境中实现控释。这些系统利用在固态肿瘤中观察到的渗透性和滞留性 (EPR) 效应来实现位点特异性递送，从而增强治疗效果并降低脱靶毒性。此外，已开发出使用配体（例如抗体、胜肽和适体）的结合系统，用于主动靶向癌症特异性受体，例如 HER2、EGFR 和 CD44，从而实现个人化和精准的癌症治疗策略。

新兴技术如何扩展癌症药物传递的能力？

技术融合正在迅速扩大NDDS在肿瘤学领域的应用范围和有效性。能够响应pH值、温度、酵素和氧化还原梯度等刺激的智慧奈米颗粒，能够根据肿瘤微环境客製化按需释放药物。例如，pH敏感的脂质体在血液循环中稳定，但在肿瘤的酸性环境中释放其有效载荷。磁感应药物载体和超音波触发奈米气泡也正在研究中，用于微创局部给药。

另一个前沿领域是将影像功能与药物传递结合，从而建构集诊断和治疗于一体的诊疗平台。此类系统可即时监测药物分布和肿瘤反应，从而製定个人化治疗方法。此外，基于干细胞和树突状细胞的外泌体递送平台因其固有的生物相容性和逃避免疫检测的能力，正在被探索，有望提供一种类似隐形的药物递送方法。

生物分解性的水凝胶、可植入的储存库和可吸入的奈米颗粒正在拓展静脉注射以外的给药途径。这些系统提高了患者的依从性，并能够为胶质母细胞瘤、胰腺癌和大肠直肠癌等固体癌提供局部缓释性。因新冠疫苗而普及的载mRNA脂质奈米颗粒，如今正被重新用于癌症免疫疗法，以递送肿瘤特异性抗原并刺激T细胞反应。

哪些癌症类型和治疗方法促使人们采用 NDDS？

乳癌、肺癌、卵巢和胰腺癌等固体癌因其独特的微环境和既定的分子标靶而处于 NDDS 整合的前沿。脂质体阿霉素（例如Doxil）和白蛋白结合Abraxane（ Abraxane ）是 NDDS 的商业性成功案例，与传统化疗相比，它们已证明具有安全性并可改善无恶化生存期。 HER2 标靶抗体药物复合体(ADC)，例如 ado-trastuzumab emtansine（ Kadcyla ），透过受体结合和细胞内细胞毒性的双重作用，正在彻底改变 HER2 阳性乳癌的治疗。

白血病和淋巴瘤等骨髓恶性肿瘤也受益于奈米颗粒包裹的药物和标靶蛋白质降解剂。 CAR-T细胞疗法和免疫查核点抑制剂越来越多地得到奈米颗粒递送系统的支持，用于调节肿瘤相关巨噬细胞或递送siRNA来下调免疫抑制基因。转移性和抗药性癌症的研究尤其活跃，多药奈米颗粒系统正被设计用于克服排放泵和肿瘤异质性。

从地区来看，美国在临床试验活动和商业化部署方面均处于领先地位，这得益于美国食品药物管理局（FDA）的核准和美国国家癌症研究所的资助。欧洲紧随其后，对精准医疗计画提供了强有力的监管支持。在亚太地区，中国、日本和韩国等国家正大力投资奈米医学新兴企业和製造基础设施，加速区域创新并进入全球市场。

推动癌症治疗领域 NDDS 全球市场成长的因素有哪些？

全球癌症治疗新型药物输送系统市场的成长受到多种因素的推动，包括癌症发病率上升、抗癌药物研发线不断扩展以及支持标靶治疗的临床证据日益增多。对微创和个人化治疗方案日益增长的需求，推动了对符合现代肿瘤学目标的先进输送平台的投资。

製药公司正在利用 NDDS 来改善药物，延长专利期限，开拓新的适应症，并在竞争激烈的治疗环境中实现产品线的差异化。生技新兴企业、学术研究机构和大型製药公司之间的策略联盟正在加速从实验室规模创新到临床及商业部署的转化进程。监管机构也展现出灵活性，根据突破性疗法和加速核准途径核准NDDS。

此外，付款人对基于结果的模型的兴趣正在为高成本、高效的NDDS疗法创造有利的报销环境。随着数据分析和数位生物标记物改善患者分层，这些系统将成为精准肿瘤学的基础。在材料科学、生物工程和人工智慧驱动的药物优化的推动下，癌症治疗领域的NDDS市场预计将在多种肿瘤类型、治疗环境和地理范围内强劲扩张。

部分

产品类型（奈米颗粒、栓塞颗粒）

受访公司范例

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Becton, Dickinson and Co.
  • BioNTech SE
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Celsion Corporation
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • ImmunoGen, Inc.
  • Ipsen
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

人工智慧集成

全球产业分析师正在利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global 特定产业产业SLM 的典型规范，而是建立了一个从世界各地专家收集的内容库，包括影片录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 竞赛

简介目录
Product Code: MCP39108

Global Novel Drug Delivery Systems in Cancer Therapy Market to Reach US$64.5 Billion by 2030

The global market for Novel Drug Delivery Systems in Cancer Therapy estimated at US$21.3 Billion in the year 2024, is expected to reach US$64.5 Billion by 2030, growing at a CAGR of 20.3% over the analysis period 2024-2030. Nanoparticles, one of the segments analyzed in the report, is expected to record a 18.0% CAGR and reach US$35.8 Billion by the end of the analysis period. Growth in the Embolization Particles segment is estimated at 23.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.8 Billion While China is Forecast to Grow at 26.9% CAGR

The Novel Drug Delivery Systems in Cancer Therapy market in the U.S. is estimated at US$5.8 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$15.0 Billion by the year 2030 trailing a CAGR of 26.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 16.4% and 18.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 16.9% CAGR.

Global Novel Drug Delivery Systems in Cancer Therapy - Key Trends & Drivers Summarized

Why Are Traditional Cancer Treatments Being Disrupted by Novel Drug Delivery Systems?

Conventional chemotherapy has long been plagued by systemic toxicity, poor bioavailability, and lack of tumor specificity-issues that compromise treatment efficacy and patient quality of life. Novel drug delivery systems (NDDS) are rapidly emerging as transformative technologies in oncology, offering targeted delivery of anticancer agents directly to tumor sites while minimizing damage to healthy tissues. By enhancing pharmacokinetics and overcoming drug resistance mechanisms, NDDS have redefined how clinicians approach complex and heterogeneous cancer types.

Among the most significant innovations are nanocarriers such as liposomes, dendrimers, micelles, and polymeric nanoparticles, which encapsulate cytotoxic agents and enable controlled release at the tumor microenvironment. These systems exploit the Enhanced Permeability and Retention (EPR) effect observed in solid tumors to achieve site-specific delivery. The result is a higher therapeutic index and reduced off-target toxicity. Additionally, conjugated systems using ligands such as antibodies, peptides, or aptamers are being developed to achieve active targeting of cancer-specific receptors like HER2, EGFR, and CD44, thereby enabling personalized and precision oncology strategies.

How Are Emerging Technologies Expanding Capabilities in Cancer Drug Delivery?

Technological convergence is rapidly enhancing the scope and efficacy of NDDS in oncology. Smart nanoparticles that respond to stimuli such as pH, temperature, enzymes, or redox gradients are enabling on-demand drug release, tailored to the tumor’s microenvironment. pH-sensitive liposomes, for instance, remain stable in circulation but release payloads in the acidic milieu of tumors. Magnetically guided drug carriers and ultrasound-triggered nanobubbles are also under investigation for localized delivery with minimal invasiveness.

Another frontier is the integration of imaging capabilities with drug delivery, leading to theranostic platforms that combine diagnosis and therapy in a single system. These systems allow for real-time monitoring of drug distribution and tumor response, enabling adaptive treatment regimens. Additionally, exosome-based delivery platforms derived from stem cells or dendritic cells are being explored for their innate biocompatibility and ability to bypass immune detection, providing a stealth-like approach to drug transport.

Biodegradable hydrogels, implantable reservoirs, and inhalable nanoparticles are extending delivery routes beyond intravenous administration. These systems improve patient compliance and enable localized, sustained-release formulations for solid tumors such as glioblastoma, pancreatic, and colorectal cancers. mRNA-loaded lipid nanoparticles, popularized by COVID-19 vaccines, are now being repurposed for cancer immunotherapy to deliver tumor-specific antigens and stimulate T-cell responses.

Which Cancer Types and Therapies Are Leading Adoption of NDDS?

Solid tumors such as breast, lung, ovarian, and pancreatic cancers are at the forefront of NDDS integration due to their well-defined microenvironments and established molecular targets. Liposomal doxorubicin (e.g., Doxil) and albumin-bound paclitaxel (Abraxane) are commercially successful examples of NDDS that have demonstrated improved safety and progression-free survival compared to traditional chemotherapies. HER2-targeted antibody-drug conjugates (ADCs), such as ado-trastuzumab emtansine (Kadcyla), are revolutionizing treatment for HER2-positive breast cancer, offering dual action through receptor binding and intracellular cytotoxicity.

Hematological malignancies like leukemia and lymphoma are also benefiting from nanoparticle-encapsulated drugs and targeted protein degraders. CAR-T cell therapy and immune checkpoint inhibitors are increasingly being supported by NDDS to modulate tumor-associated macrophages or deliver siRNA that downregulates immunosuppressive genes. Research is particularly intense in metastatic and drug-resistant cancers, where multi-drug nanoparticle systems are being engineered to overcome efflux pumps and tumor heterogeneity.

Regionally, the United States leads in both clinical trial activity and commercial deployment, supported by FDA approvals and National Cancer Institute funding. Europe follows with strong regulatory backing for precision medicine initiatives. In Asia-Pacific, countries like China, Japan, and South Korea are investing heavily in nanomedicine startups and manufacturing infrastructure to accelerate local innovation and global market participation.

What Is Fueling Growth in the Global Market for NDDS in Cancer Therapy?

The growth in the global novel drug delivery systems market for cancer therapy is driven by several factors, including escalating cancer prevalence, expanding oncology drug pipelines, and increasing clinical evidence supporting targeted therapies. Rising demand for minimally invasive, personalized treatment options has catalyzed investment in advanced delivery platforms that align with modern oncology goals.

Pharmaceutical companies are leveraging NDDS to extend patent life through drug reformulation, enter new indications, and differentiate their pipelines in a crowded therapeutic landscape. Strategic collaborations between biotech startups, academic labs, and pharmaceutical giants are accelerating the translational journey from lab-scale innovation to clinical and commercial deployment. Regulatory agencies are also demonstrating flexibility by approving NDDS under breakthrough therapy and accelerated approval pathways.

Moreover, payer interest in outcomes-based models is creating a favorable reimbursement climate for high-cost but high-efficacy NDDS therapies. As data analytics and digital biomarkers improve patient stratification, these systems will become cornerstones of precision oncology. With advances in materials science, bioengineering, and AI-driven drug optimization, the NDDS market in cancer therapy is poised for robust expansion across multiple tumor types, treatment settings, and geographies.

SCOPE OF STUDY:

The report analyzes the Novel Drug Delivery Systems in Cancer Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Nanoparticles, Embolization Particles)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Becton, Dickinson and Co.
  • BioNTech SE
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Celsion Corporation
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • ImmunoGen, Inc.
  • Ipsen
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Novel Drug Delivery Systems in Cancer Therapy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Surging Oncology Pipeline Throws the Spotlight on Novel Drug Delivery Systems in Cancer Therapy
    • Limitations of Conventional Chemotherapy Propel Investment in Targeted Delivery Innovations
    • Advances in Nanotechnology and Lipid Nanoparticles Accelerate Growth in Next-Gen Platforms
    • Rising Adoption of Immuno-Oncology and mRNA-Based Therapies Drives Development of Specialized Carriers
    • Collaboration With Biopharma Innovators Strengthens Commercialization of Delivery Technologies
    • Regulatory Approvals for Injectable Depot Systems Expand Use in Long-Term Cancer Management
    • Surge in Precision Medicine Initiatives Spurs Use of Patient-Specific Drug Delivery Systems
    • Tumor Microenvironment Research Accelerates Innovation in Site-Specific Delivery Vectors
    • Integration of pH-Responsive and Thermosensitive Materials Enhances Delivery Accuracy
    • Biodegradable Polymers and Carrier Systems Gain Traction for Controlled Release Applications
    • Expansion of Companion Diagnostics Market Enables Alignment With Delivery-Optimized Formulations
    • Development of Smart Capsules and Microneedle Arrays Supports Non-Invasive Delivery Modes
    • Growth in Oncology Trials Utilizing Nano-Carriers Propels Technological Validation
    • Partnerships With CDMOs Fuel Scale-Up and GMP Manufacturing of Novel Delivery Modalities
    • Government Funding for Next-Generation Oncology Platforms Strengthens Industry R&D
    • Patient Demand for Reduced Side Effects and Enhanced QoL Drives Preference for Targeted Delivery
    • Focus on Drug-Device Combination Products Expands Integration Across Multiple Delivery Routes
    • Rise in Orphan Cancer Drug Development Spurs Innovation in Niche Delivery Systems
    • Market Differentiation Strategies Among Pharma Players Fuel Investment in Novel Carriers
    • Shift Toward Outpatient Oncology Treatment Models Propels Demand for Sustained Release Formulations
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Novel Drug Delivery Systems in Cancer Therapy Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Nanoparticles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Nanoparticles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Nanoparticles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Embolization Particles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Embolization Particles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Embolization Particles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • JAPAN
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • CHINA
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: China 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • EUROPE
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • FRANCE
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: France 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • GERMANY
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Spain 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Russia 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Australia 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • INDIA
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: India 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: South Korea 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Latin America 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Argentina 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Brazil 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Mexico 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Rest of Latin America 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Middle East 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Iran 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Israel 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Saudi Arabia 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: UAE 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Rest of Middle East 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030
  • AFRICA
    • Novel Drug Delivery Systems in Cancer Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Nanoparticles and Embolization Particles Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Africa 16-Year Perspective for Novel Drug Delivery Systems in Cancer Therapy by Product Type - Percentage Breakdown of Value Sales for Nanoparticles and Embolization Particles for the Years 2014, 2025 & 2030

IV. COMPETITION